Keybank National Association OH raised its stake in Entellus Medical, Inc. (NASDAQ:ENTL) by 11.0% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 32,594 shares of the medical technology company’s stock after purchasing an additional 3,235 shares during the quarter. Keybank National Association OH owned approximately 0.15% of Entellus Medical worth $540,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Neuberger Berman Group LLC bought a new position in Entellus Medical in the second quarter valued at approximately $381,000. William Blair Investment Management LLC grew its stake in Entellus Medical by 10.5% in the second quarter. William Blair Investment Management LLC now owns 431,187 shares of the medical technology company’s stock valued at $7,140,000 after purchasing an additional 40,853 shares in the last quarter. Blair William & Co. IL grew its stake in Entellus Medical by 7.1% in the second quarter. Blair William & Co. IL now owns 95,380 shares of the medical technology company’s stock valued at $1,579,000 after purchasing an additional 6,330 shares in the last quarter. Frontier Capital Management Co. LLC grew its stake in Entellus Medical by 85.0% in the second quarter. Frontier Capital Management Co. LLC now owns 866,370 shares of the medical technology company’s stock valued at $14,347,000 after purchasing an additional 397,953 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its stake in Entellus Medical by 29.4% in the second quarter. Bank of New York Mellon Corp now owns 40,783 shares of the medical technology company’s stock valued at $675,000 after purchasing an additional 9,270 shares in the last quarter. Hedge funds and other institutional investors own 70.41% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.thecerbatgem.com/2017/09/11/keybank-national-association-oh-has-540000-holdings-in-entellus-medical-inc-entl.html.

Shares of Entellus Medical, Inc. (NASDAQ:ENTL) opened at 17.43 on Monday. Entellus Medical, Inc. has a 52-week low of $11.47 and a 52-week high of $22.63. The firm’s market capitalization is $442.22 million. The stock has a 50 day moving average price of $17.32 and a 200-day moving average price of $15.02.

Entellus Medical (NASDAQ:ENTL) last issued its quarterly earnings data on Thursday, August 3rd. The medical technology company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by $0.03. The company had revenue of $22.10 million for the quarter, compared to the consensus estimate of $21.87 million. Entellus Medical had a negative return on equity of 60.34% and a negative net margin of 41.11%. The business’s revenue for the quarter was up 18.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.27) earnings per share. Equities analysts forecast that Entellus Medical, Inc. will post ($1.61) EPS for the current year.

ENTL has been the subject of a number of analyst reports. ValuEngine downgraded Entellus Medical from a “sell” rating to a “strong sell” rating in a research note on Tuesday, May 23rd. Piper Jaffray Companies restated a “buy” rating on shares of Entellus Medical in a research note on Wednesday, July 12th. Zacks Investment Research downgraded Entellus Medical from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. BidaskClub downgraded Entellus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 8th. Finally, Canaccord Genuity set a $18.00 price target on Entellus Medical and gave the company a “hold” rating in a research note on Monday, May 22nd. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $21.71.

Entellus Medical Company Profile

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Want to see what other hedge funds are holding ENTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Entellus Medical, Inc. (NASDAQ:ENTL).

Institutional Ownership by Quarter for Entellus Medical (NASDAQ:ENTL)

Receive News & Stock Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related stocks with our FREE daily email newsletter.